Copyright
©The Author(s) 2022.
World J Gastrointest Endosc. May 16, 2022; 14(5): 320-334
Published online May 16, 2022. doi: 10.4253/wjge.v14.i5.320
Published online May 16, 2022. doi: 10.4253/wjge.v14.i5.320
Figure 1 Ultrasound for specimens.
A: In the after neoadjuvant chemotherapy cases, the residual tumor was SMT type with no exposure to the mucosal surface; B: Ultrasound showed the tumor as hypoechoic with regular borders (arrowhead); C: Pathology showed 18 mm × 18 mm, pT1b-SM3 (arrowhead). The pathological response was Grade1; D: After chemoradiotherapy, the residual tumor was ulcerative type; E: Ultrasound showed the tumor as mixed echoic with irregular borders; F: Pathology showed 45 mm × 20 mm, pT3 (arrowhead). The pathological response was Grade1.
- Citation: Yonemoto S, Uesato M, Nakano A, Murakami K, Toyozumi T, Maruyama T, Suito H, Tamachi T, Kato M, Kainuma S, Matsusaka K, Matsubara H. Why is endosonography insufficient for residual diagnosis after neoadjuvant therapy for esophageal cancer? Solutions using muscle layer evaluation. World J Gastrointest Endosc 2022; 14(5): 320-334
- URL: https://www.wjgnet.com/1948-5190/full/v14/i5/320.htm
- DOI: https://dx.doi.org/10.4253/wjge.v14.i5.320